ZA202406418B - Chromanol compounds for treatment or prophylaxis of ageing-associated disorders - Google Patents

Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Info

Publication number
ZA202406418B
ZA202406418B ZA2024/06418A ZA202406418A ZA202406418B ZA 202406418 B ZA202406418 B ZA 202406418B ZA 2024/06418 A ZA2024/06418 A ZA 2024/06418A ZA 202406418 A ZA202406418 A ZA 202406418A ZA 202406418 B ZA202406418 B ZA 202406418B
Authority
ZA
South Africa
Prior art keywords
ageing
prophylaxis
treatment
chromanol
sul
Prior art date
Application number
ZA2024/06418A
Other languages
English (en)
Inventor
Henk Henning Robert
Krenning Guido
Cornelis Van Der Graaf Adrianus
Henri Swart Daniël
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of ZA202406418B publication Critical patent/ZA202406418B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2024/06418A 2022-02-28 2024-08-21 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders ZA202406418B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2031091A NL2031091B1 (en) 2022-02-28 2022-02-28 Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
PCT/NL2023/050095 WO2023163596A1 (en) 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Publications (1)

Publication Number Publication Date
ZA202406418B true ZA202406418B (en) 2025-11-26

Family

ID=83271289

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/06418A ZA202406418B (en) 2022-02-28 2024-08-21 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Country Status (10)

Country Link
US (1) US20250177384A1 (https=)
EP (1) EP4486317A1 (https=)
JP (1) JP2025506844A (https=)
CN (1) CN118742301A (https=)
AU (1) AU2023225518A1 (https=)
CA (1) CA3252944A1 (https=)
CL (1) CL2024002555A1 (https=)
NL (1) NL2031091B1 (https=)
WO (1) WO2023163596A1 (https=)
ZA (1) ZA202406418B (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP2680838A1 (en) 2011-02-28 2014-01-08 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2015148522A1 (en) 2014-03-24 2015-10-01 Seals Douglas R Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
EP3672593B1 (en) * 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
US20250177384A1 (en) 2025-06-05
CN118742301A (zh) 2024-10-01
AU2023225518A1 (en) 2024-09-12
EP4486317A1 (en) 2025-01-08
NL2031091B1 (en) 2023-09-07
CL2024002555A1 (es) 2025-01-10
JP2025506844A (ja) 2025-03-13
WO2023163596A1 (en) 2023-08-31
CA3252944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
ZA202206837B (en) Compounds for treatment of alzheimer's disease
MX2022010011A (es) Inhibidores de prmt5 novedosos.
GEP20257750B (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
EP4491199A3 (en) Gadolinium bearing pcta-based contrast agents
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
EA200501617A1 (ru) Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
ZA202100981B (en) Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
DE60324544D1 (de) Muskarin antagonisten
ES2180936T3 (es) Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados.
MX2025004959A (es) Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3)
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
ZA202303774B (en) Chromanol compounds for treatment of heart failure
NO20054095L (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
MX2024003645A (es) Derivados de piridinilacetamida como activadores de canales de sodio.
ZA202406418B (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
MX2023004677A (es) Moduladores de la via de respuesta integrada al estres.
PH12020551734A1 (en) Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms
WO2001079180A3 (en) 5-substituted tetralones as inhibitors of ras farnesyl transferase
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors